JP Morgan Maintains Overweight on AtriCure, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Robbie Marcus has maintained an Overweight rating on AtriCure (NASDAQ:ATRC) and raised the price target from $30 to $40.

October 30, 2024 | 3:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan has maintained an Overweight rating on AtriCure and increased the price target from $30 to $40, indicating a positive outlook.
The increase in price target from $30 to $40 by JP Morgan suggests a positive outlook for AtriCure, likely leading to a short-term increase in stock price. The Overweight rating indicates confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100